NCT07135453 Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
| NCT ID | NCT07135453 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Alabama at Birmingham |
| Condition | Vaccine |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2026-07 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 70 participants in total. It began in 2026-07 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Eligibility Criteria
Inclusion Criteria: * Healthy adult Exclusion Criteria: * No prior history of pneumococcal vaccination * No immunosuppressing medications or chronic diseases that affect immune function
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07135453 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Vaccine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07135453 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07135453 currently recruiting?
Yes, NCT07135453 is actively recruiting participants. Contact the research team at dlafon@uabmc.edu for enrollment information.
Where is the NCT07135453 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT07135453 clinical trial?
NCT07135453 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 70 participants.